PDCD1 and hepatocellular carcinoma: Immune checkpoint inhibitors targeting PD‐1/PD‐L1 have displayed favorable efficacy in clinical settings.[66] However, the effectiveness of immunotherapy for HCC is limited, with a response rate of <30%, which could be attributed to immune microenvironment tolerance, inadequate tumor antigen exposure, and insufficient infiltration of T cells in HCC.[67, 68] Therefore, immunotherapy is commonly used as an adjunctive therapy, along with other traditional therapies, to improve the overall treatment outcomes, potentially hindering tumor reappearance and dissemination.